Literature DB >> 11313836

Peyronie's disease in men under age 40: characteristics and outcome.

A Tefekli1, E Kandirali, H Erol, T Alp, T Köksal, A Kadioğlu.   

Abstract

Peyronie's disease is most commonly seen in the fifth decade of life. However, a wide range of age (20-83 y) is reported. During a 6-year period, men with Peyronie's disease presenting under the age of 40 were reviewed retrospectively and followed-up. The prevalence of Peyronie's patients presenting under age 40 was 8.2%. Their mean age was 32.47 +/- 5.37 (range: 23-39) y and 78.9% of them presented during the acute phase of the disease. Pain on erection was a part of presenting symptom complex in 52.6% and the majority (84%) had a degree of penile curvature < 60 degrees. Erectile dysfunction (ED) was present in 21% of patients, who responded well to intracavernous injection test. After a minimal 2-year follow-up, improvement in penile deformity was observed in 36.8%, and 42.1% had stable disease while 21% experienced deterioration of the penile curvature. The onset of Peyronie's disease is clinically more noisy and acute in patients presenting under age 40 and this forces the physicians to treat them more vigorously.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313836     DOI: 10.1038/sj.ijir.3900635

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  10 in total

Review 1.  The Genetic Basis of Peyronie Disease: A Review.

Authors:  Amin S Herati; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2016-01-08

2.  Autologous testicular tunica vaginalis graft in Peyronie's disease: a prospective evaluation.

Authors:  Yernur Ainayev; Ulanbek Zhanbyrbekuly; Abduzhappar Gaipov; Nurlan Kissamedenov; Ulan Zhaparov; Makhmud Suleiman; Saltanat Urazova; Nurila Rakhmetova; Dulat Turebayev; Nurbol Keulimzhayev; Rano Zhankina; Gafur Khairli
Journal:  Int Urol Nephrol       Date:  2022-05-03       Impact factor: 2.370

3.  The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie's disease.

Authors:  Can Tuygun; Ugur Hakki Ozok; Adnan Gucuk; I Halil Bozkurt; M Abdurrahim Imamoglu
Journal:  Int Urol Nephrol       Date:  2008-07-01       Impact factor: 2.370

Review 4.  The Natural History of Peyronie's Disease.

Authors:  Fabrizio Di Maida; Gianmartin Cito; Luca Lambertini; Francesca Valastro; Girolamo Morelli; Andrea Mari; Marco Carini; Andrea Minervini; Andrea Cocci
Journal:  World J Mens Health       Date:  2020-07-08       Impact factor: 5.400

5.  Clinical and epidemiological characteristics of young patients with Peyronie's disease: a retrospective study.

Authors:  Gianni Paulis; Giorgio Cavallini; Davide Barletta; Paolo Turchi; Antonio Vitarelli; Andrea Fabiani
Journal:  Res Rep Urol       Date:  2015-07-09

Review 6.  Psychosexual Symptoms and Treatment of Peyronie's Disease Within a Collaborative Care Model.

Authors:  Rose Hartzell
Journal:  Sex Med       Date:  2014-12       Impact factor: 2.491

7.  The Prevalence of Peyronie's Disease in the United States: A Population-Based Study.

Authors:  Mark Stuntz; Anna Perlaky; Franka des Vignes; Tassos Kyriakides; Dan Glass
Journal:  PLoS One       Date:  2016-02-23       Impact factor: 3.240

Review 8.  All about Peyronie's disease.

Authors:  Ahmed A Hussein; Amjad Alwaal; Tom F Lue
Journal:  Asian J Urol       Date:  2015-04-16

9.  Contemporary cost-analysis comparison of direct-to-consumer vs. traditional prescriptions of phosphodiesterase-5 inhibitors.

Authors:  Douglas Schneider; Charles A Loeb; Andrew Brevik; Farouk El-Khatib; Lawrence C Jenkins; Faysal A Yafi
Journal:  Int J Impot Res       Date:  2022-04-09       Impact factor: 2.896

10.  Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study.

Authors:  Gianni Paulis; Davide Barletta; Paolo Turchi; Antonio Vitarelli; Giuseppe Dachille; Andrea Fabiani; Romano Gennaro
Journal:  Res Rep Urol       Date:  2015-12-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.